NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

2 years ago

PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a…

Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million

2 years ago

Press ReleaseNicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 millionNCX 470 therapeutic profile positively received…

Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure

2 years ago

PRESS RELEASE US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARAInitial data expected in Q4…

BioSenic provides further update on negotiations with its main creditors

2 years ago

 INSIDE INFORMATION Agreement with the main creditors of BioSenic for a standstill running until October 2023 Mont-Saint-Guibert, Belgium, July 10th,…

BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call

2 years ago

July 7, 2023News Release BioPorto A/S to Host Second Quarter 2023 Earnings Webcast and Analyst Call COPENHAGEN, Denmark and BOSTON,…

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2 years ago

CLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered…

SmileDirectClub to Report Second Quarter 2023 Results on August 8, 2023

2 years ago

NASHVILLE, Tenn., July 07, 2023 (GLOBE NEWSWIRE) -- SmileDirectClub, Inc. (Nasdaq: SDC), the next generation oral care company with the…

Xtant Medical Announces Closing of $15 Million Private Placement

2 years ago

BELGRADE, Mont., July 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company…

European Patent Granted for ZyVersa Therapeutics’ Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease

2 years ago

Cholesterol Efflux Mediator™ VAR 200 is in phase 2a development to reduce renal cholesterol and lipid accumulation that damages the kidneys'…

AMN Healthcare to Hold Second Quarter 2023 Earnings Conference Call on Thursday, August 3, 2023

2 years ago

DALLAS, July 07, 2023 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss…